Take our survey

We value your opinion. To improve your experience on emend.com, we are conducting research to better understand the needs of our visitors.

Please take a few moments to complete a short 5-question survey.

Please be assured that this survey is for research purposes only and that your privacy will be respected. Your responses will remain strictly confidential.

Any data collected in this survey will be handled in accordance with the privacy policy of Vovici, who is administering this survey on behalf of Merck.

Your responses to this survey will be kept strictly confidential and WILL NOT be used to contact you or sell you products or information.

This survey is sponsored by Merck.

Take now Take later No thanks
Emetogenic

The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
Merck
chart
a
Study design: Data from 2 multicenter, randomized, double-blind, parallel-group, controlled clinical trials that compared the regimen including EMEND with an active control regimen in chemotherapy-naive patients (N=1,105) receiving a chemotherapy regimen that included cisplatin >50 mg/m2. The most common primary diagnoses were respiratory and urogenital carcinomas.21,22

Significantly more patients on the regimen with EMEND achieved complete response as compared with those on an active-control regimen

chart
Continued 
b
Because patients could use rescue medication for nausea and/or vomiting, the end point “no use of rescue medication” is a surrogate for “no nausea.”21,22
  • In Study 2, the percentage of patients on the regimen with EMEND who achieved complete response as compared with those on an active-control regimen was similar to Study 1 (63% vs 43%, P<0.001).

Selected Important Risk Information

EMEND should be used with caution in patients receiving concomitant medications that are primarily metabolized through CYP3A4. Inhibition of CYP3A4 by EMEND could result in elevated plasma concentrations of these concomitant medications. Conversely, when EMEND is used concomitantly with another CYP3A4 inhibitor, aprepitant plasma concentrations could be elevated.

Chemotherapy agents that are known to be metabolized by CYP3A4 include docetaxel, paclitaxel, etoposide, irinotecan, ifosfamide, imatinib, vinorelbine, vinblastine, and vincristine. In clinical studies, EMEND 125 mg/80 mg was administered commonly with etoposide, vinorelbine, or paclitaxel. The doses of these agents were not adjusted to account for potential drug interactions. In separate pharmacokinetic studies, EMEND 125 mg/80 mg did not influence the pharmacokinetics of docetaxel or vinorelbine.

Before prescribing EMEND or EMEND for Injection, please read the Prescribing Information. The Patient Information also is available.

For information about Merck products or services, please call 866-448-7590. The Merck National Service Center will be pleased to assist you Monday through Friday from 8 AM to 7 PM ET.

20950402(6)-07/09-EME